Roche continued to lead the Top Biopharma ranks, nearly larger than the next three companies combined, but we saw a new entrant at the bottom of our list, as Eylea, Regeneron’s treatment for wet AMD, pushed it ahead of the floundering Dendreon. Next year, AbbVie will drop Amgen to the #3 position in our list, a weirder development than we could have imagined a few short years ago.
None of our Top Biopharmas saw negative sales in 2012, unlike their Pharma counterparts. We’ll see how well that holds up in few years, when biosimilars begin to chip away at U.S. and EU sales for some of the major biologics. Total drug revenues were up 6% to $96.4 billion, while earnings rose 9% to $26.0 billion.
Note: a company qualifies as a “Biopharma” if it makes at least 50% of its drug revenues from selling biologics and vaccines. Small-molecule companies need not apply.
—Gil Y. Roth
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Baxter, by Kristin Brooks
The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)
Pipeline information compiled by Kristin Brooks
Revenue information compiled by Gil Roth
Top 10 Biopharma Companies
based on 2012 biopharma revenues
2012 R&D Expenditures
Note: In all Top Company profiles, dollar amounts are in millions.